Kornimate/medical-research-clean huggingface dataset:
a panel of biomarkers in diagnosing late-onset neonatal sepsis and necrotizing enterocolitis in sibu hospital

Conditions: Neonatal SEPSIS; Necrotizing Enterocolitis

Summary: this is a cross-sectional study to evaluate the utilities of a panel of biomarkers (procalcitonin, interleukin-6, serum amyloid a and apolipoprotein c2) versus the gold standard blood culture result diagnosing late-onset neonatal sepsis (lons) and/or necrotizing enterocolitis (nec). neonates who meet the initial screening criteria for suspected lons or nec will be recruited into the study. a group of 50 neonates who are clinically well, admitted to the nursery or general ward for reasons other than neonatal sepsis or nec will also be recruited into the study.

the diagnosis of neonatal sepsis is challenging especially the very low birth weight infants as the signs and symptoms of sepsis are nonspecific and can be attributed to non-infected aetiologies including exacerbation of bronchopulmonary dysplasia, apnoea of prematurity and gastroesophageal reflux. blood culture remains the gold standard for diagnosing septicaemia (either bacteremia or fungemia). however, its effectiveness in the population of preterm infants is compromised.given the dire consequences of not treating the sepsis early, clinicians tend to have a low threshold for treatment. this leads to overuse of antimicrobials, promotion of antimicrobial resistance, exposure of infants to avoidable side effects from the antimicrobial treatment, prolonged hospitalisation and increased healthcare costs. hence, there is a need for a clearly defined algorithm for diagnosing lons and nec. this study aims to examine the diagnostic utilities of a panel of sepsis biomarkers and explore if they can be incorporated into a diagnostic algorithm which hopefully, can be translated into clinical practice in the future.

Eligibility criteria:
neonates with suspected lons/nec inclusion criteria: * infants with signs and symptoms suggestive of sepsis and/or nec and requiring full sepsis screening and start of intravenous antibiotic(s), or a change of antibiotics (if already on) * infants with postnatal age greater than 72 hours and less than 28 days of life, of all gestation * parents of potential neonates who are willing to give written informed consent healthy subjects inclusion criteria: * clinically well infants admitted to sibu hospital for reasons other than neonatal sepsis or nec * infants with postnatal age greater than 72 hours and less than 28 days of life, of all gestation exclusion criteria: * infants who have lethal or life-threatening congenital abnormalities * infants who have chromosomal abnormalities * infants who have hypoxic ischemic encephalopathy * infants who are on steroid treatment * infants who received blood transfusions * post-operative infants
i change adherence & raise expectations

Conditions: Cystic Fibrosis

Summary: the icare study, a clustered-randomized controlled trial, is evaluating an adherence promotion intervention for adolescents that cystic fibrosis (cf) care teams will implement. half the centers will receive the comprehensive adherence program (cap) for 2 years. cap consists of training in the cf my way program (a validated problem-solving adherence promotion intervention). the other half of the centers will receive cap in year 2 of the study. participants are patients age 11-20 years old who are diagnosed with cf and have been prescribed at least one of the following medications for at least 6 months prior to signing the informed consent: azithromycin, hypertonic saline, pulmozyme®, tobi®, or inhaled compounded tobramycin. rate of refilling prescriptions is the primary outcome with lung function decline rates, exacerbation rates, and patient reported measures including health related quality of life and cf knowledge and skills, as secondary outcomes. a central goal of this study is to test the effectiveness of the comprehensive adherence program (cap), described above, versus standard care (sc) for adolescents and young adults seen in outpatient cf clinics.


Eligibility criteria:
inclusion criteria: * male or female patients age 11 - 20 years old * patients with a diagnosis of cf * patients attend the accredited care center for regularly scheduled clinic visits * patient must be prescribed at least one of the following medications for at least 6 months prior to signing the informed consent: azithromycin hypertonic saline pulmozyme® tobi® inhaled compounded tobramycin -patient has consented to provide data to the cf foundation registry prior to conversion to portcfv2 exclusion criteria: * patient is planning to change care teams within the next 2 years * patient is seen at a satellite clinic * patient is on the lung transplant list (note: participation in this study will not delay or exclude patient from being placed on the transplant list in the future or receiving a transplant once enrolled in the study)

Keywords: cystic fibrosis adherence problem-solving adolescents education skills remediation
couples therapy to enhance intimacy between patients with advanced or recurrent prostate cancer and their partners

Conditions: Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Sexual Dysfunction; Sexuality and Reproductive Issues

Summary: rationale: a couples therapy program may enhance intimacy and reduce psychological distress in patients with prostate cancer and in their partners. purpose: this randomized clinical trial is studying how well couples therapy enhances intimacy and reduces psychological distress in patients with advanced or recurrent prostate cancer and in their partners.

objectives: * determine the feasibility of intimacy-enhancing couples therapy (iect) for patients with advanced or recurrent prostate cancer and their partners. * compare the effect of iect vs usual care on patients' and their partners' level of global psychological distress. * compare the effect of iect vs usual care on relationship intimacy in these participants. outline: this is a randomized, controlled, pilot, multicenter study. patients are stratified according to marital distress based on partners' scores on the abbreviated dyadic adjustment scale (high \[\< 21\] vs low \[≥ 21\]). patients and their partners are randomized to 1 of 2 arms. * arm i: patients and their partners receive intimacy-enhancing couples therapy over 6 weeks comprising the following four 90-minute sessions: the story of cancer; understanding the couple, ways of relating and key influences; intimacy; and coping, support, and adaptation. patients and their partners complete treatment satisfaction questionnaires after completion of study intervention. * arm ii: patients and their partners receive standard psychosocial care. all participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention.

Eligibility criteria:
disease characteristics: * diagnosis of primary prostate cancer * advanced or recurrent disease * receiving concurrent hormonal therapy * married and/or co-habitating with a partner for ≥ 1 year * t-score \> 50 on brief symptom inventory-18 questionnaire (patient and/or partner) patient characteristics: * normal cognitive functioning * able to speak and read english * no significant hearing impairment that would preclude study participation prior concurrent therapy: * see disease characteristics

Keywords: psychosocial effects of cancer and its treatment sexual dysfunction sexuality and reproductive issues recurrent prostate cancer stage iii prostate cancer stage iv prostate cancer
study of the safety and efficacy of adalimumab in subjects with moderate to severely active psoriatic arthritis subjects with inadequate response to disease modifying anti-rheumatic drug therapy

Conditions: Arthritis; Psoriatic

Summary: multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severely active psoriatic arthritis subjects with inadequate response to disease modifying anti-rheumatic drug therapy


Eligibility criteria:
inclusion criteria: * moderate to severe psa * inadequate response to dmard therapy * corticosteroid stable dose \<=10 mg qd * dmards must have been taken for 3 months and stable dose for 4 weeks * mtx maximum dose = \<=30 mg/week * active chronic plaque ps or documented history of chronic plaque ps exclusion criteria: * no other active skin disease
use of dexmedetomidine in children undergoing oral maxillofacial surgery to decrease emergence delirium

Conditions: Delirium

Summary: the purpose of this study is to determine whether dexmedetomidine is effective in the treatment of emergence delirium of preschool children undergoing oral maxillofacial surgery.

emergence delirium is a common side effect of sevoflurane anesthesia in children. dexmedetomidine, because of its sedative and analgesic properties, might be useful for the management of this adverse effect. in the pediatric population, it has been shown to provide sedation for magnetic resonance imaging. intravenously, it is has been shown to decrease emergence delirium following sevoflurane based anesthesia. the ability to administer a medication intravenously might solve the problem of emergence delirium and emergence agitation posed by the young patients undergoing oral maxillofacial surgery.

Eligibility criteria:
inclusion criteria: * preschool children undergoing oral maxillofacial surgery exclusion criteria: * mental diseases * history of neural system disease * sedative medication history * anticipated difficult airway

Keywords: dexmedetomidine emergence delirium sevoflurane anesthesia preschool children oral maxillofacial surgery
thrive, a computerized cognitive behavior therapy program to treat depression

Conditions: Depressive Symptoms

Summary: this study evaluates a culturally-modified version of thrive, a computerized cognitive behavior therapy program to treat depressive symptoms, syndromes, and disorders among rural montanans. study participants will be randomized to either a wait-list treatment as usual or the thrive program. after 8 weeks, the wait-list group will then receive thrive. the primary assessment measure is the patient health questionnaire-9.

montana ranks high among states on mental health disorder prevalence and low on access to mental health care. it has the highest suicide rate in the nation. of montana's 56 counties, 10 are classified as rural and 45 as frontier, accentuating distance challenges in accessing care. new treatment delivery modalities are needed to complement, supplement and augment traditional mental health care. with increase in access to the internet, computer-administered cognitive behavior therapy (ccbt) programs have emerged as viable approaches to effective treatment of depression. thrive is an interactive ccbt program with a heavy emphasis on video rather than text content that appears to improve participant engagement, a shortcoming seen in prior ccbt programs. the goal of this project is to conduct a randomized wait-list controlled of thrive to determine its effectiveness in reducing depressive symptom severity among montanans, many of whom have few or no other options for mental health treatment.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * baseline phq-9 score of 5 or greater * montana resident * regular access to broadband internet (streaming capability) exclusion criteria: * no broadband internet access * aged 17 years or younger * does not have montana residency * baseline phq-9 score of \< 5

Keywords: cognitive behavior therapy
haemophilia patients with inhibitors being treated for acute joint bleeds

Conditions: Congenital Bleeding Disorder; Haemophilia A; Haemophilia B

Summary: this trial is conducted in africa, asia, europe, japan, and north and south america. the aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor vii analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.


Eligibility criteria:
inclusion criteria: * 12 years of age or older (at least 18 years in croatia, france and united kingdom (uk)) * clinical diagnosis of congenital haemophilia a or b with a current positive inhibitor titre and a known peak inhibitor of above 5 bethesda units (bu) (present or in the past) to human fviii or ix and known antihuman fviii or ix anamnestic response * minimum of 2 joint bleeds (haemarthroses of ankles, knees, or elbows) requiring haemostatic drug treatment within the previous 6 months, or at least 4 joint bleeds (hemarthroses of ankles, knees, or elbows) requiring haemostatic drug treatment within the previous 12 months at trial entry exclusion criteria: * known allergy to rfviia, and/or suspected allergy to trial product * platelet count lower than 50,000 mm\^3 based on medical records at trial entry (visit 1) * any clinical signs or history of thromboembolic events * advanced atherosclerotic disease * severe liver disease based on medical records within the past 12 months at trial entry (visit 1), as defined by alanine aminotransferase (alat) above 3 times the upper limit of normal reference range * known active pseudo tumours (documented bleeding requiring treatment within the last 3 months * subject had any (major) surgical procedure in the 30 days prior to screening into the trial. a. catheter, ports and dental extractions do not count as surgeries and will not exclude the subject
etiology and prognosis of sich based on hemorrhage location

Conditions: Spontaneous Intracerebral Hemorrhage

Summary: the investigators retrospectively collected participants with spontaneous cerebral hemorrhage(sich) from january 2015 to december 2019 for training and internal validation. clinical and imaging data were collected. modified rankin scale (mrs) scores were determined good outcome as "mrs = 0-2", poor outcome as "mrs = 3-6". the location features of sich were extracted by symptom mapping. noncontrast computed tomography images of patients and hematoma masks were registered with standard human brain templates to identify specific affected brain regions. then a probability map of hemorrhage for different causes and prognosis is generated. pyradiomics was used to extract the radiomic features, integrate radiomic and clinical features into multiple logistic regression models, and develop and validate optimal etiological and prognostic models. further tests were performed in an independent cohort. the area under the working characteristic curve (auc), sensibility, specificity were used to evaluate the reliability of the model.


Eligibility criteria:
inclusion criteria: * the confirmation of intracranial hemorrhage was achieved through ncct. exclusion criteria: * they presented with secondary hemorrhage resulting from head trauma, hemorrhagic transformation of ischemic infarction, brain tumors, or exhibited abnormalities in blood coagulation, liver, kidney function, or were subject to drug-induced cerebral hemorrhage * only postoperative ct images were available * lost follow-up records * ct image artifacts

Keywords: normative analysis; lesion-symptom mapping; radiomics; etiological classification; machine learning
efficacy and tolerance of jak inhibitors in atu for atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the aim is to assess effectiveness (easi, scorad, iga, dlqi, pruritus, sleep loss) and safety (clinical and biological adverse events) of jak inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life french multicenter retrospective cohort


Eligibility criteria:
inclusion criteria: * adults * moderate to severe atopic dermatitis * treated by jak inhibitors between december 2020 and september 2021 * inefficiency, loss of efficiency or contra-indication of previous systemic agent, dupilumab or phototherapy * ineligibility to french ongoing clinical trials exclusion criteria: * children * mild atopic dermatitis * eligibility to ciclosporine, methotrexate, dupilumab, phototherapy * eligibility to french ongoing clinical trials * patients' opposition for the use of their records * follow up \<3 months

Keywords: effectiveness safety jak inhibitors atopic dermatitis adults
a clinical and radiographic evaluation of low-level diode laser full pulpotomy in vital permanent teeth

Conditions: Irreversible Pulpitis; Endodontic Inflammation

Summary: in this study, patients with symptoms of irreversible pulpitis in mature permanent molars were treated with two pulpotomies techniques after random allocation in either 2 groups: diode laser pulpotomy and traditional pulpotomy using bioactive materials (retro mineral trioxide aggregate ) with each group.the null hypothesis of the study was there would be no difference in success rate between diode laser and traditional methods of adult pulpotomy .

in this study, 40 patients with symptoms of irreversible pulpitis in mature permanent 1st and 2nd molars were treated with two pulpotomy techniques after random allocation in either 2 groups: traditional pulpotomy and low-level diode laser pulpotomy. the pulp in each group was capped with retro mta . in the traditional pulpotomy group, the coronal pulp was removed by the traditional method while in the low-level diode laser pulpotomy group, the radicular pulp was biostimulated using low-level diode laser beam with parameters (970nm, power .5watt, duty cycle 50%, and frequency 5h) 10 sec for each pulp stump in non-contact mode. after that, the capping material was prepared as manufacturer's instructions and applied over the pulp stamp, the final restoration was then placed in both groups. patients were followed up after 6, 12, and 18 months to evaluate success and failure.

Eligibility criteria:
inclusion criteria: * permanent 1st and 2nd molar * irreversible pulpitis * restorable exclusion criteria: * non-restorable teeth. * teeth with buccal restoration. * non-vital teeth that are not responsive to thermal stimuli or electric pulp test. * presence of swelling or sinus tracts. * teeth which showed sensitivity to percussion. * teeth with grade ⅱ and ⅲ mobility. * teeth with immature apices. * teeth with internal or external resorption or teeth with periapical pathosis.

Keywords: full pulpotomy low-level diode laser
evaluation of skeletal muscle lipid content by magnetic resonance spectroscopy

Conditions: Healthy

Summary: type 2 diabetes is a growing public health issue and one component of type 2 diabetes is 'insulin resistance" - the ability of insulin to work less well. the skeletal muscle is one of the largest users of sugar in the body, when the skeletal muscle is "insulin resistant", this contributes to diabetes. there is some evidence that the amount of fat in the skeletal muscle is related to the amount of insulin resistance. we are asking people to participate in a study to look at the amount of fat in muscle and how this fat amount changes with exercise. we hypothesize that heavier people will have higher amounts of fat and deplete this fat more slowly than lean subjects.

high intramyocellular lipid (imcl) content in skeletal muscle has been correlated to insulin resistance in obese subjects. yet, endurance athletes have high intramyocellular lipid content and very low insulin resistance. there are several explanations for this paradox. this study will use a new magnetic resonance imaging technique to look at the amount of fat in the muscle and its depletion with exercise. we hypothesize that overweight subjects will have higher amounts of fat and deplete this fat more slowly than lean subjects.

Eligibility criteria:
inclusion criteria: * age range will be from age 18 to 45. we will be limiting the upper age range because increased age is associated with sarcopenia and alteration of fiber type. * we will define the lean trained group by a bmi of \ 26 25 kg/m2. * the subjects should be participating in regular running exercise (\> 30 min/day, ≥ 5 days/week). * weight must be stable \[+/- 5 pounds\] for at least the three months prior to the study for all participants. exclusion criteria: * the subjects must not be on medications that may affect lipid levels, specifically lipid lowering agents, birth control pills, or diuretics. * the subjects should not be on a high fat diet (\> 45% fat) as measured by a screening questionnaire. * the subject must not have any contraindications to magnetic resonance imaging.

Keywords: training intramyocellular lipid insulin resistance
sleep apnea in paralympic ontario-resident athletes with spinal cord injury (sports) study

Conditions: Sleep Apnea; Breathing Disorder During Sleeping; Sleep Disorder; Spinal Cord Injuries; Spine Disease

Summary: this single arm clinical trial will assess whether continuous positive airway pressure (cpap) therapy in the management of moderate-to-severe sleep-related breathing disorders (srbds) among para-athletes living with cervical/thoracic, complete or incomplete spinal cord injury (sci) is effective in improving cognitive impairment, in reducing fatigue, depression, anxiety, and overall quality of life. further, the study will evaluate the effectiveness of cpap therapy in improving their performance in sports and the perceived risk of injuries.

untreated moderate-to-severe srbds are associated with an increased risk of stroke, heart attack, diabetes, and kidney problems. for para-athletes living with sci, it can have a major negative impact on their performance when practicing and playing sports. cpap therapy is the treatment of choice for moderate-to-severe srbd (or sleep apnea) in accordance with current good medical practices. therefore, the aim of the study is to determine whether cpap therapy in para-athletes living with sci who developed moderate-to-severe srbds is effective in improving memory, psychosocial implications, social and work participation, and performance in sports.

Eligibility criteria:
inclusion criteria: * individuals with a cervical or thoracic, complete or incomplete (ais a to d), chronic (\> 6 months) sci; * english-speaking adults (18 years of age or older); and * play a wheelchair sport at a high-performance level. exclusion criteria: * a previous history of diagnosis and treatment for sleep apnea; * concomitant diseases of the central nervous system and other pre-existing diseases of the central nervous system; * current substance misuse; * history of primary hypersomnia, or secondary hypersomnia of any cause except for srbds. * conditions that might prevent participants to follow the study protocol.

Keywords: sleep-related breathing disorders sleep apnea spinal cord injuries para-athletes spinal diseases sports
adverse effects of ivermectin used in egypt during covid-19

Conditions: Covid19; Ivermectin Poisoning; Drug Toxicity; Drug Side Effect

Summary: retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt

ivermectin was used in egypt during the pandemic of covid-19 and it was registered in the moh protocol that has been published in november 2020 the study will document the adverse effects of many patients used ivermectin as aprophylaxis and as a treatment with multiple dose regimens

Eligibility criteria:
inclusion criteria: * all people used ivermectin as a treatment or as a prophylactic in covid 19 pandemic in egypt with explained dose exclusion criteria: -